Biofourmis

Biofourmis is a global digital HealthTech start-up focused on remote patient monitoring and personalised predictive care. By harnessing AI, they’re advancing the practice of medicine by detecting personalised patterns predictive of patient’s health deterioration.

Biofourmis Care provides a holistic, customisable solution to deliver virtual care to patients with acute, post-acute, and chronic medical conditions. It enables care providers to receive notifications as patient conditions change as the patient is monitored continuously and in real-time, and offer care based on context-rich patient insights, and intervene early when needed, reducing readmissions and associated costs.

Biofourmis has built BiovitalsHF, a personalised physiological data analytics engine based on human physiology that formulates personalised health models, resulting in highly optimised post-acute patient monitoring solutions and accurate prediction of patient health deterioration before it happens. They use connected devices and bio-sensors to capture physiological signals and detect anomalies. This AI-empowered continuous monitoring platform alerts medical professionals to intervene days before a critical event. This technological-enabled integrated care delivery allows for remote communication, diagnosis, monitoring, ​and intervention. The dual-edged diagnostic precision and early-intervention results in improved health outcomes and lower healthcare costs.

Biofourmis reached unicorn status following a $300M Series D funding round, in April 2022. The Boston-based company is now valued at $1.3B. The fresh capital will help the company to fund clinical trials.

Biofourmis was founded by scientists, and cardiologists in September 2015, focused on combining clinicians’ knowledge of biological mechanism that drives the human body and diseases and advanced machine learning techniques to enable the machine to find personalised patterns predictive of patient’s health deterioration.